REPLIMUNE GROUP INC. - COMMON STOCK

Replimune to Host Virtual Investor Event on March 30, 2022

21 Mar 2022 05:00:01 By Nasdaq GlobeNewswire

Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 05:00:00 By Nasdaq GlobeNewswire

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

03 Feb 2022 05:00:02 By Nasdaq GlobeNewswire

Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

31 Jan 2022 13:01:00 By Nasdaq GlobeNewswire

Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones

10 Jan 2022 04:00:02 By Nasdaq GlobeNewswire

Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 05:00:03 By Nasdaq GlobeNewswire

Replimune Appoints Christy Oliger to its Board of Directors

02 Dec 2021 05:00:02 By Nasdaq GlobeNewswire

Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

12 Nov 2021 04:00:02 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

04 Nov 2021 05:00:02 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 Nov 2021 05:00:01 By Nasdaq GlobeNewswire

Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

01 Oct 2021 05:01:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

06 Aug 2021 05:00:00 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

02 Aug 2021 05:00:01 By Nasdaq GlobeNewswire

Replimune to Present at the William Blair Biotech Focus Conference 2021

07 Jul 2021 05:00:02 By Nasdaq GlobeNewswire

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

03 Jun 2021 04:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update

20 May 2021 05:00:02 By Nasdaq GlobeNewswire

Replimune Appoints Tanya Lewis as Chief Development Operations Officer

10 May 2021 05:00:00 By Nasdaq GlobeNewswire

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

05 May 2021 04:00:01 By Nasdaq GlobeNewswire

Replimune to Host Virtual Investor Event on June 3, 2021

28 Apr 2021 05:00:01 By Nasdaq GlobeNewswire

Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer

21 Apr 2021 05:00:01 By Nasdaq GlobeNewswire